Literature DB >> 21904918

Neurologic manifestations of Chagas disease.

Marco Oliveira Py1.   

Abstract

Chagas disease is endemic in Latin America and has become an emerging problem in developed countries because of international migrations. The protozoan Trypanosoma cruzi is the etiologic agent and the disease is divided into two phases. The acute phase is mostly asymptomatic or presents with unspecific symptoms. Rarely, a severe and often fatal form occurs in immunosuppressed patients or infants, characterized by meningoencephalitis (sometimes including brain tumor-like lesions) and myocarditis. The chronic phase consists of an indeterminate, asymptomatic form followed by digestive, cardiac, or neurologic symptoms in about 30% of infected patients. Autonomous nervous system dysfunction is prominent in chagasic patients and participates in the affliction of the target organs. Stroke, mainly cardioembolic, may occur in the chronic phase, but other stroke etiologies are reported. Embolic sources and inflammation are thought to play a role in stroke mechanisms. Specific treatment for Chagas disease is scarce and preventive measures are needed.

Entities:  

Mesh:

Year:  2011        PMID: 21904918     DOI: 10.1007/s11910-011-0225-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  41 in total

1.  Autonomic dysfunction in Chagas disease: lack of participation of the vagus nerve.

Authors:  M B Mahler-Araújo; L Chimelli
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Jul-Aug       Impact factor: 2.184

2.  [Embolic cerebral vascular accidents in chronic Chagas' heart disease].

Authors:  I NUSSENZVEIG; B L WAJCHEMBERG; R MACRUZ; A S F NETTO; J TIMONER; L G DO SERRO AZUL
Journal:  Arq Neuropsiquiatr       Date:  1953-12       Impact factor: 1.420

3.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

Authors:  Jose Antonio Marin-Neto; Anis Rassi; Carlos A Morillo; Alvaro Avezum; Stuart J Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf
Journal:  Am Heart J       Date:  2008-07       Impact factor: 4.749

4.  American trypanosomiasis (Chagas' disease): an unrecognised cause of stroke.

Authors:  F J Carod-Artal; A P Vargas; M Melo; T A Horan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

5.  Cardiac thrombosis and thromboembolism in chronic Chagas' heart disease.

Authors:  J Samuel; M Oliveira; R R Correa De Araujo; M A Navarro; G Muccillo
Journal:  Am J Cardiol       Date:  1983-07       Impact factor: 2.778

6.  A population-based study of the association between Trypanosoma cruzi infection and cognitive impairment in old age (the Bambuí Study).

Authors:  M Fernanda Lima-Costa; Erico Castro-Costa; Elizabeth Uchôa; Joselia Firmo; Antonio Luiz P Ribeiro; Cleusa P Ferri; Martin Prince
Journal:  Neuroepidemiology       Date:  2008-12-16       Impact factor: 3.282

7.  Late reactivation of Chagas' disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy.

Authors:  Paulo Euripedes Marchiori; Paula Levatti Alexandre; Nise Britto; Roseli A Patzina; A Alfredo Fiorelli; Leandro T Lucato; Sergio Rosemberg; Samira L Apostolos Pereira; Noedir Groppo Stolf; Milberto Scaff
Journal:  J Heart Lung Transplant       Date:  2007-10-24       Impact factor: 10.247

8.  The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease.

Authors:  J Antonio Marin-Neto; Anis Rassi; Alvaro Avezum; Antonio C Mattos; Anis Rassi; Carlos A Morillo; Sergio Sosa-Estani; Salim Yusuf
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 9.  [Neurological effects of American trypanosomyiasis: clinical aspects].

Authors:  Fidias E León-Sarmiento; Diddier G Prada; Jaime Bayona-Prieto; Vladimir Valderrama; Ingrid García; Marta E León; Dan Sunnemark
Journal:  Biomedica       Date:  2003-12       Impact factor: 0.935

10.  Neurological manifestations in Chagas disease without cardiac dysfunction: correlation between dysfunction of the parasympathetic nervous system and white matter lesions in the brain.

Authors:  Marco Py; Roberto Pedrosa; Juliana Silveira; Aline Medeiros; Charles Andre
Journal:  J Neuroimaging       Date:  2008-10-21       Impact factor: 2.486

View more
  13 in total

1.  High-Level Expression in Escherichia coli, Purification and Kinetic Characterization of LAPTc, a Trypanosoma cruzi M17-Aminopeptidase.

Authors:  Maikel Izquierdo; Mirtha Elisa Aguado; Martin Zoltner; Jorge González-Bacerio
Journal:  Protein J       Date:  2019-04       Impact factor: 2.371

2.  Stroke in Chagas disease: from pathophysiology to clinical practice.

Authors:  Thaís Aparecida Reis Lage; Julia Teixeira Tupinambás; Lucas Bretas de Pádua; Matheus de Oliveira Ferreira; Amanda Cambraia Ferreira; Antonio Lucio Teixeira; Maria Carmo Pereira Nunes
Journal:  Rev Soc Bras Med Trop       Date:  2022-06-06       Impact factor: 2.141

3.  Protective effect of aspirin treatment on mouse behavior in the acute phase of experimental infection with Trypanosoma cruzi.

Authors:  Arturo Silvero-Isidre; Sergio Morínigo-Guayuán; Aaron Meza-Ojeda; Marcelo Mongelós-Cardozo; Claudia Centurión-Wenninger; Susy Figueredo-Thiel; Diego F Sanchez; Nidia Acosta
Journal:  Parasitol Res       Date:  2017-12-01       Impact factor: 2.289

4.  Causing Mechanisms of Embolic Strokes in Chagas Heart Disease: Autonomic Dysfunction, a Working Hypothesis.

Authors:  Roberto Coury Pedrosa
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

5.  Variability of Oral and Pharyngeal Transit Between Two Consecutive Swallows in Chagas' Disease.

Authors:  Roberto Oliveira Dantas; Carla Manfredi Dos Santos; Rachel de Aguiar Cassiani; Weslania Viviane do Nascimento
Journal:  Gastroenterology Res       Date:  2013-09-09

Review 6.  Infectious disease-associated encephalopathies.

Authors:  Maria C Barbosa-Silva; Maiara N Lima; Denise Battaglini; Chiara Robba; Paolo Pelosi; Patricia R M Rocco; Tatiana Maron-Gutierrez
Journal:  Crit Care       Date:  2021-07-06       Impact factor: 9.097

7.  Oral exposure to Phytomonas serpens attenuates thrombocytopenia and leukopenia during acute infection with Trypanosoma cruzi.

Authors:  Rosiane V da Silva; Aparecida D Malvezi; Leonardo da Silva Augusto; Danielle Kian; Vera Lúcia H Tatakihara; Lucy M Yamauchi; Sueli F Yamada-Ogatta; Luiz V Rizzo; Sergio Schenkman; Phileno Pinge-Filho
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

8.  Infective causes of stroke in tropical regions.

Authors:  Ali Moghtaderi; Roya Alavi-Naini
Journal:  Iran J Med Sci       Date:  2012-09

9.  Acute Chagas disease induces cerebral microvasculopathy in mice.

Authors:  Lindice Mitie Nisimura; Vanessa Estato; Elen Mello de Souza; Patricia A Reis; Marcos Adriano Lessa; Hugo Caire Castro-Faria-Neto; Mirian Claudia de Souza Pereira; Eduardo Tibiriçá; Luciana Ribeiro Garzoni
Journal:  PLoS Negl Trop Dis       Date:  2014-07-10

Review 10.  Acute chagas disease: new global challenges for an old neglected disease.

Authors:  Daniela V Andrade; Kenneth J Gollob; Walderez O Dutra
Journal:  PLoS Negl Trop Dis       Date:  2014-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.